Here's What to Expect From Eli Lilly’s Next Earnings Report

Core Insights - Eli Lilly and Company is a leading global pharmaceutical firm focused on innovative treatments for various diseases, including diabetes, obesity, Alzheimer's, cancer, and autoimmune disorders [1] - The company has announced an investment exceeding $1 billion to enhance its manufacturing and supply capabilities in India, highlighting its commitment to global growth and addressing health needs [2] - Eli Lilly's market capitalization stands at $768.85 billion [2] Financial Performance - Eli Lilly is expected to report a significant profit growth of 441.5% year-over-year for Q3 fiscal 2025, projecting earnings of $6.39 per diluted share [3] - For the current fiscal year, analysts anticipate a profit increase of 77.1% from the previous year, estimating earnings of $23.01 per diluted share [4] - The company reported a 38% year-over-year revenue increase to $15.56 billion for Q2 fiscal 2025, with non-GAAP EPS rising 61% to $6.31 [6] Stock Performance - Over the past 52 weeks, Eli Lilly's stock has declined by 9.5%, while it has gained 7.1% year-to-date [5] - In comparison, the S&P 500 Index has increased by 14.7% over the same 52-week period [5] - The Health Care Select Sector SPDR Fund has seen a decline of about 6.7% over the past year but has risen 3.6% year-to-date [5] Recent Developments - Following the release of Q2 results, Eli Lilly's stock experienced a 14% intraday drop due to disappointing efficacy results from its weight-loss drug candidate, Orforglipron, in Phase 3 trials [6]